Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacillus subtilis + enterococcus faecium + multivitamins
- Development stage
- Phase 4
- Lead developer
- Hanmi Pharmaceutical
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
- Administration
- Oral
01
Overview
This product is a combination of two probiotic bacterial strains, *Bacillus subtilis* and *Enterococcus faecium*, with added multivitamins. Both bacteria are well-established probiotics used to support gut health, restore intestinal flora balance, and enhance immune function. - **Bacillus subtilis** is a spore-forming bacterium known for its resilience in the gastrointestinal tract; it can survive stomach acid and bile salts, supporting the growth of beneficial gut bacteria and producing metabolites that help maintain intestinal homeostasis[5][8]. - **Enterococcus faecium** is a lactic acid-producing bacterium naturally found in the human gut. It lowers intestinal pH, inhibits pathogenic bacteria through competitive exclusion and production of bacteriocins, and supports immune modulation[6][7]. - **Multivitamins** provide essential micronutrients that may support overall health but do not directly contribute to probiotic activity. The combination aims to synergistically improve digestive health by replenishing beneficial microflora (especially after antibiotic use), reducing gastrointestinal symptoms such as bloating or diarrhea, enhancing nutrient absorption from food (with vitamin support), modulating inflammation, improving metabolic status (e.g., lipid profiles), and supporting immune function[2][4][5][7].
- Brand names
- 妈咪爱Medilac-Vita
- Other names
- Live Combined Bacillus Subtilis and Enterococcus Faecium Granules with Multivitamines枯草杆菌、肠球菌二联活菌多维颗粒剂枯草杆菌二联活菌颗粒
02
Targets
Shigella spp. (Shigella species)
Beyond the preview
Go deeper on bacillus subtilis + enterococcus faecium + multivitamins.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacillus subtilis + enterococcus faecium + multivitamins.